Skip to content

Ananda Developments - Appointment of Scientific Advisers

Announcement provided by

Ananda Developments Plc · ANA

23/01/2024 07:00

Ananda Developments - Appointment of Scientific Advisers
RNS Number : 5025A
Ananda Developments PLC
23 January 2024



("Ananda" or the "Company")


Ananda appoints Scientific Advisers


Ananda Developments Plc ('Ananda'), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions, is pleased to announce the appointment of Professor Cherry Wainwright and Dr. Katie Sloper, PhD as scientific advisers to assist the Company in developing its in-house capabilities and pipeline of clinical trials.


Professor Cherry Wainwright is a pharmacological research expert with over 42 years of experience and is the President Elect of the British Pharmacological Society ('BPS'), a charity with a mission to promote and advance the whole spectrum of pharmacology (the scientific study of the effects of drugs and chemicals on living organisms).  The BPS leads the way in the research and application of pharmacology around the world and has over 4,000 members from more than 60 countries worldwide. Cherry will advise the Company on its drug development activities, areas of potential unmet need that could benefit from Ananda's medicines, and clinical trial activities including protocol development.


Dr. Katie Sloper, PhD is a medical research expert with a particular focus on the therapeutic profile of cannabis-based medicines and innovative approaches to cancer treatment. Katie's work with Ananda will focus on developing the Company's scientific understanding of cannabidiol and its mechanisms of action, with a particular focus on chronic pain and inflammation. Katie will help the Company to continually refine its scientific approach and identify potential new areas for clinical investigation.


Ananda's Chairman, Charles Morgan, commented "Having worked with Cherry and Katie for some time, I am delighted that they are joining Ananda as scientific advisers to support our objective of gaining approval for MRX's cannabis-based formulations to be used in the NHS.  Strengthening our team with these highly regarded scientists will both enhance our scientific capabilities and help us to target our research and development efforts even more effectively. It is also a huge opportunity for Ananda to explore new areas of potential unmet need where our cannabinoid medicines could benefit patients"


Adviser Biographies


Professor Cherry Wainwright

Cherry graduated from the University of Aberdeen with a BSc (Hons) in Pharmacology and subsequently the University of Strathclyde with a PhD in Cardiovascular Pharmacology. Her research career spans more than 42 years, with over 20 years spent at Strathclyde University before moving to Robert Gordon University in Aberdeen where she spent 8 years as the Director of the multi-disciplinary Institute for Health & Wellbeing Research and was the lead in Cardiometabolic Health Research and Co-Director of the Centre for Natural Products in Health. 


Throughout her career, Cherry has worked continuously in collaboration with industry conducting research on the identification of novel therapeutic targets of cardiovascular diseases. For the last 20 years her focus has been on the influence of endocannabinoids and phytocannabinoids on various cardiovascular disorders (ischaemia/reperfusion, cardiac fibrosis), vascular (atherosclerosis, restenosis) injury and cardiac energy regulation. 


Cherry has published around 100 full original articles and invited reviews and holds 3 patents. She is a Fellow of the British Pharmacological Society, for which she is currently President Elect. 


Dr. Katie Sloper, PhD

Katie graduated from the University of New England with a BSc in Biochemistry, Microbiology and Nutrition, receiving several university Prizes for Excellence. Katie was then the recipient of the University Medal at the Australian National University (ANU) for her Honours thesis on DNA damage repair pathways. Katie subsequently completed her PhD at ANU with a focus on cancer research, before completing postdoctoral fellowships in both Australia and the USA.


In addition to her medical research Katie has over 15 years working in healthcare across both public and private sectors, including as a Senior Policy Advisor to the Queensland Minister for Health and a Member of the Pharmacy Board of Australia. Katie's medical research has recently focussed on understanding the therapeutic profile of cannabis-based medicines and investigating innovative approaches to cancer treatment.


To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:  


·              Investor Hub:

·              Instagram:   

·              LinkedIn:   

·              Twitter:

·              Investor Meet Company:



The Directors of the Company accept responsibility for the contents of this announcement.


For more information please contact:


Engage with us directly at Ananda Developments Investor Hub


Sign up at


Chief Executive Officer

Melissa Sturgess

Executive Director

Jeremy Sturgess-Smith


+44 (0)7463 686 497


Corporate Finance

Richard Morrison

Harry Davies-Ball

+44 (0)20 3470 0470

Corporate Broking

Abigail Wayne

Rob Rees


Yellow Jersey PR

Charles Goodwin

Soraya Jackson

+44 (0)20 3004 9512



About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based

medicines for the treatment of complex, chronic inflammatory pain conditions.


For further information on the Company visit or sign up at


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

ANA announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal